Abarceo Pharma AB
Adam Bruce is a seasoned executive with extensive experience in the pharmaceutical and biotech sectors. Currently serving as Chief Executive Officer, Founder, and Board Member at TikoMed AB since March 2002, Adam Bruce has been instrumental in driving the company's vision and growth. Additionally, Adam Bruce holds the position of Chairman at Abarceo Pharma, focusing on innovative solutions for Type 2 Diabetes. Ownership of WaveSeven AB since 2014 further underscores entrepreneurial aspirations. Adam Bruce's previous roles include Working Chairman and CEO at TikoMed AB during its early years, contributing significantly to its development. Academic credentials include studies at Lund University and participation in various executive education programs.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Abarceo Pharma AB
Abarceo Pharma is a spin out of Lund University Diabetes Center and is located in Malmo Sweden. Scientific founders Prof. Claes Wollheim, MD and Associate Prof. Albert Salehi are world-class experts in beta cell biology. Abarceo Pharma is a Lund University Holding company and was founded in December 2017. The company is dedicated to developingnovel therapeutics for type-2 diabetes based upon a deep molecular and genetic understanding of the disease.